NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.

The company has already kicked off an open-label Phase I trial of ABX1100 in Canada following positive results from a study of healthy volunteers.

The company is still seeking strategic options for its development programs, including nana-val, which it was testing in EBV-positive refractory lymphoma.

The firm will make its artificial intelligence-based Lunit SCOPE IO platform available to SITC member researchers.

The Department of Health and Social Care is gauging whether AI technology can increase the number of patients screened by each radiologist.

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Thirty patients have received the gene therapy within a clinical trial and early-access program, and the foundation also hopes to seek approval in the US.